Cleveland Clinic Abu Dhabi receives American College of Cardiology accreditation for excellence in Cardiac Catheterization and Percutaneous Coronary Intervention

Hospitals receiving Cardiac Cath Lab Accreditation with PCI from the ACC must undergo a comprehensive clinical process, including gap analysis, care variance review, action plan development, onsite evaluation, and ongoing monitoring
Cleveland Clinic Abu Dhabi's Heart, Vascular & Thoracic Institute (HVTI) continues to set new benchmarks in advanced cardiac care in the region. In 2024, HVTI performed 839 procedures, including 574 cardiac surgeries and 265 structural heart interventions.
Abu Dhabi, United Arab Emirates.: Cleveland Clinic Abu Dhabi, part of the M42 group, has earned the prestigious recognition from the American College of Cardiology (ACC) for its excellence in treating patients requiring cardiac catheterization procedures. Cleveland Clinic Abu Dhabi was awarded Cardiac Cath Lab Accreditation with Percutaneous Coronary Intervention (PCI) following a rigorous onsite evaluation of the staff's ability to evaluate, diagnose and treat patients in its state-of-the-art cardiac catheterization laboratory. Percutaneous coronary intervention, commonly known as coronary angioplasty, is a non-surgical procedure that opens narrowed or blocked coronary arteries with a balloon to relieve symptoms of heart disease or reduce heart damage during or after a heart attack.
The hospital has also been recognized by the ACC as an International Center of Excellence for its commitment to comprehensive, high-quality culture and cardiovascular care. This designation is awarded to international hospitals that consistently demonstrate excellence through comprehensive process improvement, disease and procedure-specific accreditation, professional excellence, and community engagement. Cleveland Clinic Abu Dhabi is the Center of Excellence for adult cardiac surgery as accredited by the Department of Health- Abu Dhabi.
Cleveland Clinic Abu Dhabi's Heart, Vascular & Thoracic Institute (HVTI) continues to set new benchmarks in advanced cardiac care in the region. In 2024, HVTI performed 839 procedures, including 574 cardiac surgeries and 265 structural heart interventions, showcasing its expertise in treating complex heart conditions. Since 2015, the institute has successfully completed 500 TAVI procedures, reflecting its leadership in minimally invasive heart treatments. The institute's Coronary Artery Disease Program further unites multidisciplinary experts including cardiologists, interventional cardiologists, and cardiac surgeons to provide comprehensive, individualized care for patients. Renowned for its leadership in robotically assisted and hybrid surgeries, HVTI is recognized as one of the world's leading centers and leads Cleveland Clinic's facilities in the United States for robotically assisted heart surgery.
Dr. Georges-Pascal Haber, CEO at Cleveland Clinic Abu Dhabi said: 'This accreditation is a powerful testament to Cleveland Clinic Abu Dhabi's dedication to advancing healthcare excellence. It reflects our relentless drive to combine cutting-edge innovation, world-class expertise, and a patient-first philosophy to redefine the standards of care in the region. This milestone not only highlights the exceptional work of our Heart, Vascular & Thoracic Institute but also reinforces our commitment to leading the way in transforming cardiovascular care for patients in the UAE and beyond. As we continue to push the boundaries of what's possible in medicine, we remain steadfast in our mission to improve lives and deliver unparalleled care."
Deepak L. Bhatt, MD, MPH, FACC, chair of the ACC Accreditation Management Board said: 'Cleveland Clinic Abu Dhabi has demonstrated its commitment to providing patients in UAE and from across the world with excellent heart care. The hospital has proven to be a forward-thinking institution with goals to advance the cause of sustainable quality improvement. ACC Accreditation Services is proud to award Cleveland Clinic Abu Dhabi with Cardiac Cath Lab Accreditation with PCI.'
Hospitals receiving Cardiac Cath Lab Accreditation with PCI from the ACC must take part in a multi-faceted clinical process that involves completing a gap analysis, examining variances of care, developing an action plan, a rigorous onsite review, and monitoring for sustained success. Improved methods and strategies of caring for patients include streamlining processes, implementing guidelines and standards, and adopting best practices in the care of cath lab patients. Facilities that achieve accreditation meet or exceed an array of stringent criteria and have organized a team of doctors, nurses, clinicians, and other administrative staff that earnestly support the efforts leading to improved patient outcomes.
Dr. Ronney Shantouf, Director of the Cardiac Catheterization Lab, co-Director of the Complex Coronary Program, and co-Director of the Invasive Coronary Spasm and Microvascular Dysfunction Program at Cleveland Clinic Abu Dhabi said: 'This accreditation is a proud moment for Cleveland Clinic Abu Dhabi and reflects our dedication to providing the highest standards of cardiac care. Advances in cardiac catheterization procedures, such as percutaneous coronary intervention, have transformed the way we treat complex heart conditions, offering patients safer and less invasive options with faster recovery times. At Cleveland Clinic Abu Dhabi, we combine state-of-the-art technology with a highly skilled team to ensure each patient receives tailored, life-saving care. This recognition is a testament to our ongoing commitment to improving outcomes and enhancing the quality of life for our patients."
Hospitals that have proven exceptional competency in cardiac catheterization follow strict processes to ensure quality and patient safety. During the procedure, they careful manage steps like sedation, infection control, radiation safety, and time out procedures to ensure everything is fully coordinated. They also need to master the appropriate transfer to a cath recovery unit to better monitor and track complications, enhance physician-to-patient communication, patient family communication, discharge instructions and follow-up information.
About Cleveland Clinic Abu Dhabi
Cleveland Clinic Abu Dhabi, part of the M42 group, is a multispecialty hospital located on Al Maryah Island in Abu Dhabi, UAE. As an extension of Cleveland Clinic in the U.S., it is uniquely designed to address the complex and critical care needs of the UAE and the broader region. The hospital is organized into specialized Institutes, including Heart, Vascular & Thoracic; Neurological; Cancer; Digestive Disease; Medical Subspecialties; Integrated Surgical Subspecialties; Integrated Hospital Care; and Diagnostic.
Celebrating its 10th anniversary in 2025, Cleveland Clinic Abu Dhabi is a 405-bed hospital, including 321 acute care beds, 84 critical care beds, four royal suites, and 26 operating rooms. Its state-of-the-art facilities provide patients in the region with direct access to world-class healthcare providers and Cleveland Clinic's renowned model of care. The hospital is also home to the Fatima bint Mubarak Center, a dedicated cancer center offering comprehensive diagnostics and advanced treatment across 24 clinical departments, covering a range of cancer subspecialties and programs. Committed to medical innovation, Cleveland Clinic Abu Dhabi integrates robotics across specialties, pioneers endovascular therapy and hybrid procedures, and offers comprehensive programs in heart failure, heart transplantation, and limb salvage.
Licensed by the Department of Health – Abu Dhabi as a designated research and teaching facility, Cleveland Clinic Abu Dhabi drives medical innovation through clinical trials and advanced research to enhance patient care. It is the first hospital in the UAE accredited by both the Accreditation Council for Graduate Medical Education International (ACGMEI) and the Accreditation Council for Continuing Medical Education (ACCME), offering residency and fellowship programs, undergraduate health professional training, and Continuing Medical Education (CME).
M42 is a global, tech-enabled healthcare company based in Abu Dhabi, operating at the forefront of medical advancement.
About the American College of Cardiology
The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Al Etihad

5 days ago

• Al Etihad

Cleveland Clinic Abu Dhabi delivers first infusion therapy for Parkinson's in region

17 June 2025 11:31 ABU DHABI (WAM) Cleveland Clinic Abu Dhabi, part of the M42 group, has successfully introduced continuous infusion therapy, a cutting-edge therapeutic treatment for advanced Parkinson's disease, making it the first hospital in the GCC region to offer this innovative therapy offers a groundbreaking alternative for patients who are not candidates for DBS or prefer a non-invasive all patients in the advanced stages of Parkinson's are eligible for it. It delivers a continuous subcutaneous infusion of levodopa-carbidopa—the gold-standard medication for Parkinson's—through a compact pump connected to the skin. Unlike oral medications, which can lead to fluctuating absorption and inconsistent symptom control, this approach provides a steady, around-the-clock infusion, ensuring more stable symptom post-treatment follow-ups are significantly reduced to once every six months, compared to the frequent monitoring required after DBS surgery, making it a more convenient long-term option for by an exceptional team of Parkinson's disease specialists providing 24/7 care, alongside a dedicated rehabilitation team and other medical professionals, Cleveland Clinic Abu Dhabi ensures patients receive the highest level of comprehensive, patient-centred on bringing advanced and tailored treatment solutions to the region, Dr. Georges-Pascal Haber, the CEO of Cleveland Clinic Abu Dhabi, said, 'The introduction of continuous therapy in the UAE and GCC represents a critical advancement in how we approach patient care and outcomes in the region. As neurodegenerative diseases become more prevalent, patients are increasingly in need of personalised, innovative solutions.'Highlighting the impact of the therapy, Dr. Shivam Om Mittal, Staff Physician, Neurological Institute at Cleveland Clinic Abu Dhabi, who led the treatment, said, 'We are proud to be the first in the region to offer this groundbreaking therapy so soon after its global introduction. At Cleveland Clinic Abu Dhabi, we provide a full spectrum of advanced Parkinson's treatments—including oral medication, deep brain stimulation (DBS), and now this treatment, ensuring each patient receives a personalised care plan. Additionally, our exceptional team of Parkinson's disease specialists, supported by a dedicated rehabilitation team and other medical professionals, ensures 24/7 care and comprehensive support for our patients at every stage of their journey.'The infusion system functions much like an insulin pump, with a compact, phone-sized device connected to a fine tube placed on the skin. It delivers a continuous infusion of Parkinson's medication throughout the day and night, maintaining stable drug levels and significantly reducing motor fluctuations and innovation is transforming how we manage advanced Parkinson's disease, offering patients greater stability, independence, and an improved quality of life. Additionally, its straightforward design makes it easy to implement, providing a seamless transition for both patients and Parkinson's disease being the fastest-growing neurodegenerative condition worldwide—expected to double by 2040—the need for innovative, effective treatments has never been more urgent. Currently, 1% of individuals over 60 years old are affected globally, with an increasing number of young-onset cases under 50 being its introduction in 2019 by Cleveland Clinic Abu Dhabi, deep brain stimulation (DBS) surgery has been the leading advanced treatment for Parkinson's in the UAE. The hospital has now successfully performed over 100 Clinic Abu Dhabi, through the pioneering introduction of continuous infusion therapy in the GCC, is leading the charge in neurological marks a significant step forward in the UAE's ambition to become a global hub for medical innovation. With its multidisciplinary approach to patient care, where neurology, surgery, rehabilitation, and other specialities collaborate seamlessly, it continues to set new standards in advancing treatment options that transform patient outcomes and improve lives across the region.

Gulf Today

11-06-2025

• Gulf Today

UAE performs first robotic surgery with HIPEC

Cleveland Clinic Abu Dhabi has successfully performed the UAE's first robotic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) to treat a rare appendiceal tumour, in a medical milestone that reinforces Abu Dhabi's position as a global destination for innovative healthcare. The complex procedure, performed on a 48-year-old patient, involved the removal of multiple internal organs to prevent the spread of the tumour in her abdomen. This groundbreaking procedure was led by Dr Yasir Akmal, Staff Physician in the Digestive Disease Institute at Cleveland Clinic Abu Dhabi and an American Fellowship-trained surgical oncologist, and a multi-disciplinary team. Appendiceal tumours account for less than 1 per cent of malignancies worldwide and are found in approximately 1.4 per cent of patients who undergo an appendectomy. The patient initially presented symptoms resembling appendicitis, leading to the removal of her appendix. However, during the procedure, her surgeon discovered gelatinous deposits, a jelly-like substance, in the abdominal cavity. A subsequent pathology report confirmed the presence of a rare low-grade mucinous neoplasm, a tumour that, if untreated, could spread throughout the abdomen and result in a condition known as pseudomyxoma peritonei or 'jelly belly.' Dr Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, said, 'We are pushing the boundaries of robotic surgery and are proud to have used such an advanced technology for a complex procedure like Paola's. Cleveland Clinic Abu Dhabi is a leader in surgical innovation, continuously refining minimally invasive techniques to improve outcomes and enhance quality of life.' Following the tumour removal, HIPEC treatment (Hyperthermic Intraperitoneal Chemotherapy) was administered- a technique where heated chemotherapy (42 degrees Celsius) is circulated within the abdominal cavity for 90 minutes to eliminate any residual cancer cells. Highlighting both the preventive and curative nature of the surgery, Dr Akmal said that the patient's condition was diagnosed at an advanced but treatable stage, and thanks to the timely intervention of the multidisciplinary team, supported by specialised AI-driven diagnostic tools, the team was able to navigate the process of eliminating the cancer cells in her body with precision. WAM

Dubai Eye

09-06-2025

• Dubai Eye

Abu Dhabi carries out first robotic surgery to remove appendiceal tumour

A 48-year-old patient with a rare appendiceal tumour has become the first in Abu Dhabi to undergo a robotic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC). Dr. Yasir Akmal, Staff Physician in the Digestive Disease Institute, led a multi-disciplinary team at Cleveland Clinic Abu Dhabi to perform the complex procedure. It involved the removal of multiple internal organs to prevent the spread of the tumour in the patient's abdomen, and the administration of the HIPEC treatment where heated chemotherapy (42 degrees Celsius) is circulated within the abdominal cavity to eliminate any residual cancer cells. The patient, who initially presented symptoms resembling appendicitis, was undergoing a procedure to remove the organ when the surgeons discovered gelatinous deposits (jelly-like substance) in the abdominal cavity. A subsequent pathology report confirmed the presence of a rare low-grade mucinous neoplasm, a tumour that, if untreated, could spread throughout the abdomen and result in a condition known as pseudomyxoma peritonei or 'jelly belly". Dr. Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, highlighted that the "minimally invasive techniques... (helps) improve outcomes and enhance quality of life". According to the official stats, appendiceal tumours account for less than 1 per cent of malignancies worldwide and are found in approximately 1.4 per cent of patients who undergo an appendectomy. Highlighting both the preventive and curative nature of the surgery, Dr. Akmal said that the patient's condition was diagnosed at an advanced but treatable stage, and thanks to the timely intervention of the multidisciplinary team, supported by specialised AI-driven diagnostic tools, the team was able to navigate the process of eliminating the cancer cells in her body with precision.